Evidence map›Paper›PMID 25548441›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2015

Lack of Correlation Between the CCR5-Δ32 Mutation and Acute Myeloid Leukemia in Iranian Patients.

Hossein Khorramdelazad, Yousef Mortazavi, Mohammad Momeni, Mohammad Kazemi Arababadi, Behjat Kalantary Khandany, Mozhgan Moogooei, Gholamhossein Hassanshahi

Open access · bronzeAbstract read
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The key role of astrocyte elevated gene-1 in CCR6-induced EMT in cervical cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hossein KhorramdelazadMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Yousef MortazaviDepartment of Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, 4513956111 Zanjan, Iran.
Mohammad MomeniDepartment of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Mohammad Kazemi ArababadiDepartment of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran ; Immunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Behjat Kalantary KhandanyDepartment of Hematology-Oncology and BMT, Kerman University of Medical Sciences, Kerman, Iran.
Mozhgan MoogooeiMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Gholamhossein HassanshahiMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Rafsanjan University of Medical Sciences · IRKerman University of Medical Sciences · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemokines and their receptors are crucially important in the pathogenesis of acute myeloblastic leukemia (AML). The CC chemokine receptor 5 (CCR5) is a specific chemokine receptor for CC chemokine ligand 3 (CCL3), CCL4 and CCL5 which all play key roles in identifying cancer properties and localization of leukemia cells. It has been demonstrated that the known mutation in CCR5 gene (CCR5-Δ32) leads to mal-expression of the receptor and affect its function. The aim of this study was to determine the rate of CCR5-Δ32 mutation within Iranian AML patients. In this study, blood samples were obtained from 60 AML patients and 300 healthy controls. The CCR5-Δ32 mutation was evaluated using Gap-PCR technique. Our results showed that CCR5-Δ32 mutation was not found in the patients, while three out of the controls had hetrozygotic form of this mutation. The rest of studied samples had the wild form of the gene. According to these findings, it can probably be concluded that the CCR5-Δ32 is not associated with susceptibility to AML in Iranian patients.

Indexed as

Acute myeloblastic leukemiaCCR5-Δ32 mutationChemokine

Identifiers

PMID25548441
PMCPMC4275532
OpenAlexW2043046047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.